13 Result(s)
-
Article
Open AccessKIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway
Multiple myeloma (MM) is an incurable hematological malignancy characterized by clonal proliferation of malignant plasma B cells in bone marrow, and its pathogenesis remains unknown. The aim of this study was ...
-
Article
Open AccessPan-cancer analysis of DDIT4 identifying its prognostic value and function in acute myeloid leukemia
Acute myeloid leukemia (AML) is a hematological malignancy derived from the accumulation of abnormal proliferation of infantile leukocytes in the hematopoietic system. DNA-damage-inducible transcript 4 (DDIT4) ac...
-
Article
Open AccessEfficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
This multicenter, open-label, single-arm trial (ClinicalTrials.gov, NCT05236621) was conducted to confirm the efficacy and safety of generic pomalidomide plus dexamethasone in Chinese patients with relapsed or...
-
Article
Open AccessIbrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study
Waldenström’s macroglobulinemia (WM) is a rare malignant B cell lymphoma which occurs in around 1–2% of all hematologic tumors. Ibrutinib was approved in China for WM on the basis of two global pivotal studies...
-
Article
Open AccessN6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21cip1/waf1/CDK2-Cyclin E1 axis-mediated cell cycle transition
Multiple myeloma (MM) is the second most common hematological malignancy. N6-methyladenosine (m6A) is the most abundant RNA modification. YTH domain-containing family protein 2 (YTHDF2) recognizes m6A-cotaining R...
-
Article
Novel insights into roles of N6-methyladenosine reader YTHDF2 in cancer progression
N6-methyladenosine (m6A) is the most abundant RNA modification. M6A RNA methylation is reversible: m6A is installed by “writers”, removed by “erasers”, and recognized by “readers”. Readers are executors to regula...
-
Article
Open AccessImportance of circulating adipocytokines in multiple myeloma: a systematic review and meta-analysis based on case-control studies
Adipocytes and their products, adipocytokines, play important roles in the generation and development of multiple myeloma (MM). Studies have demonstrated some adipocytokines to be associated with MM, although ...
-
Article
Management of cytokine release syndrome related to CAR-T cell therapy
Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely used to treat hematological malignancies, including acute leukemia, lymphoma, and multiple myeloma. Despite its...
-
Article
Infusion of leukocytes from HLA haplo-identical familial donors as an adjuvant in the HLH-2004 protocol to treat the virus-associated adult hemophagocytic lymphohistiocytosis: a retrospective study of 26 patients
Adult hemophagocytic lymphohistiocytosis (HLH) is a fatal disease with poor survival and a limited role of drug therapies. To help to recognize virus and enhance survival, we infused leukocytes derived from hu...
-
Article
Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes
Cytotoxic T lymphocytes (CTLs) play a critical role in the control of leukemia. However, few effective CTL epitopes have been identified to date yet. We previously reported that MLAA-22, a protein composed of ...
-
Article
Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine
Homeostasis-driven proliferation of T cells is an important means of reconstituting T-cell-dependent immunity after lymphodepletion regimens, such as chemotherapy or radiotherapy. Immune-reconstituted mice tha...
-
Article
Detection of serum tumor markers in multiple myeloma using the CLINPROT system
The discovery of biomarkers unique to multiple myeloma (MM) is of great importance to clinical practice. This study was designed to identify serum tumor marker candidates of MM in the mass range of 700–10000 D...
-
Article
Quantitative assessment of MLAA-34 expression in diagnosis and prognosis of acute monocytic leukemia
MLAA-34 is a newly identified monocytic leukemia-associated antigen. Previous data indicated that MLAA-34 might be a novel anti-apoptosis factor related closely to carcinogenesis or progression of acute monocy...
